In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and Alzheimer's disease.
❓ Unknown
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial
Just now
November 19, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
This article reports on a medical research trial at the University of Colorado studying immune system treatment for Down syndrome, with no connection to Iran or Iranian affairs.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
10 min ago •
Foreign Ministry Statement on Iran's Defensive Strikes Against U.S. Military Bases and Assets
13 min ago •
Spectral clues suggest hollow-core magnetic jet in brightest-ever gamma-ray burst
13 min ago •